SCHEMBL19206635

SCHEMBL19206635

Cc1ccc2cccc(C(=O)Nc3ccccc3)c2n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.61
GAA P10253 1/20 0.61
PARP1 P09874 1/20 0.59
NPC1 O15118 5/20 0.57
RAB9A P51151 4/20 0.57
CASP3 P42574 1/20 0.57
SENP8 Q96LD8 1/20 0.57
SENP7 Q9BQF6 1/20 0.57
SENP6 Q9GZR1 1/20 0.57
HPGD P15428 2/20 0.55
TP53 P04637 2/20 0.54
EGLN1 Q9GZT9 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52
CD38 P28907 1/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
ALDH1A1 P00352 2/20 0.51
ALOX12 P18054 1/20 0.51
GBA1 P04062 1/20 0.49
KDM4E B2RXH2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21532932 0.90 NPC1 (0.71) MAPTGAAPARP1NPC1RAB9A
SCHEMBL21532953 0.87 RAB9A (0.56) MAPTGAAPARP1NPC1RAB9A
SCHEMBL21532931 0.85 RAB9A (0.57) MAPTGAAPARP1NPC1RAB9A
SCHEMBL21532952 0.85 NPC1 (0.55) MAPTGAAPARP1NPC1RAB9A
SCHEMBL19206634 0.84 NR1H4 (0.57) MAPTGAAPARP1NPC1RAB9A
SCHEMBL19240119 0.83 PNLIP (0.54) MAPTGAAPARP1NPC1RAB9A
SCHEMBL19206631 0.82 PARP1 (0.59) MAPTGAAPARP1NPC1RAB9A
SCHEMBL1035548 0.81 PARP1 (0.65) MAPTPARP1NPC1RAB9ACASP3
SCHEMBL19206639 0.80 PARP1 (0.56) MAPTGAAPARP1NPC1RAB9A
SCHEMBL27772010 0.79 PARP1 (0.72) MAPTGAAPARP1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10383868-B2 Quinoline containing compounds and their use for treating endoplasmic reticulum stress-related diseases NEURODON CORPORATION 2019-08-20 US disclosed
US-20170231973-A1 QUINOLINE CONTAINING COMPOUNDS AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-RELATED DISEASES NEURODON CORPORATION 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170231973-A1 QUINOLINE CONTAINING COMPOUNDS AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-RELATED DISEASES ATP2A1, ATP2A3, ATP2A2 MAPT 1112/4885GAA 46/4885PARP1 2403/4885
US-10383868-B2 Quinoline containing compounds and their use for treating endoplasmic reticulum stress-related diseases ATP2A1, ATP2A3, ATP2A2 MAPT 1112/4885GAA 46/4885PARP1 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.